Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Emory University
Sponsor:
Information provided by (Responsible Party):
Ighovwerha Ofotokun, Emory University
ClinicalTrials.gov Identifier:
NCT01228318
First received: October 23, 2010
Last updated: May 15, 2014
Last verified: May 2014

October 23, 2010
May 15, 2014
January 2011
April 2016   (final data collection date for primary outcome measure)
C-terminal telopeptide of collagen (CTx) [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
Changes in serum CTx level from baseline through week 24 will be quantitated and subsequently compared between treatment arms.
C-terminal telopetide of collagen (CTx) [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
Changes in serum CTx level from baseline through week 24 will be quantitated and subsequently compared between treatment arms.
Complete list of historical versions of study NCT01228318 on ClinicalTrials.gov Archive Site
Bone mineral density (BMD) by Dual-energy X-ray absorptiometry (DXA)-Scan, Cellular OPG/RANKL Expression [ Time Frame: 12, 24, 48, 96, and 144 weeks ] [ Designated as safety issue: No ]
Changes in BMD, and cellular OPG/RANKL expression from baseline through week 144 will be quantitated and subsequently compared between treatment arms.
Bone mineral density (BMD by DXA-Scan, Cellular OPG/RANKL Expression [ Time Frame: 12, 24, and 48 weeks ] [ Designated as safety issue: No ]
Changes in BMD, and cellular OPG/RANKL expression from baseline through week 48 will be quantitated and subsequently compared between treatment arms.
Not Provided
Not Provided
 
Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)
Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)

With the increasing age of people living with HIV/AIDS, age-induced osteoporosis is likely to be compounded by HIV/AIDS and HAART-associated bone loss. Mechanistically, osteoclasts the cells responsible for bone resorption form under the influence of the key osteoclastogenic cytokine Receptor- Activator of NF-KB (RANKL). The osteoclastogenic and proresorptive activities of RANKL are moderated by its physiological decoy receptor osteoprotegerin (OPG). Imbalance in the ratio of RANKL to OPG alters osteoclastic bone resorption and lead to osteoporosis. Activated T- and B-cells are a major source of RANKL, while normal physiological B-cells are a major source of OPG. T-cells regulate the production of OPG by B-cells. Thus changes in the immune system induced by HIV/AIDS and/or by HAART could affect B-cell and T-cells RANKL and OPG production. Indeed, data from our group shows that in an animal model of HIV/AIDS, the HIV-1 Transgenic rat, the development of osteoporosis is recapitulated as observed in HIV-infected patients, and B-cell OPG and RANKL production are concurrently down regulated and upregulated respectively. Furthermore, preliminary data in HIV-infected subjects suggests dramatic acute upswing in bone resorption following HAART initiation that peaks at 12 weeks and then declines. Based on these findings, the investigators hypothesize HAART associated bone loss is driven by immune reconstitution. Because this effect of HAART is dramatic in magnitude but short in duration, the investigators propose to apply antiresorptive agent (zoledronic acid, reclast®) to specifically spare patients from this dramatic but acute bone damage.

In a prospective, blinded placebo-controlled randomized trial, treatment naïve HIV-infected subjects initiating HAART will be assigned to HAART + zoledronic acid or HAART + placebo. Serial assessment of serum levels of bone markers, cellular expression of OPG/RANKL and other cytokines, cellular immune activation markers, serum bone regulating hormones, and bone mineral density (BMD) by DXA scan will be undertaken at pre-defined time points from baseline through week 144 of HAART.

In the primary analysis, changes in serum CTx level, BMD, and cellular OPG/RANKL expression from baseline through week 24 will be quantitated and subsequently compared between treatment arms. In addition, the impact of zoledronic acid administration on these covariates will be assessed at various study time points. The relationship between OPG/RANKL expression, immune activation, serum bone regulating hormonal levels, and bone turnover will be evaluated.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
  • HIV Infection
  • Bone Loss
  • Osteopenia
  • Osteoporosis
Drug: Zoledronic acid
  1. A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.
  2. A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes.
Other Name: Reclast
  • Experimental: Zoledronic acid
    Subjects in this arm will receive 5mg/100mL solution of zoledronic acid infused intravenously over 15-30 minutes under the supervision of study personnel.
    Intervention: Drug: Zoledronic acid
  • Placebo Comparator: Placebo
    Subjects in the placebo arm will receive placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution administered iv over 15-30 minutes under the supervision of study personnel.
    Intervention: Drug: Zoledronic acid

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
78
June 2016
April 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. HIV-1 infection, as documented by any licensed serologic test and confirmed by a western blot or by a positive plasma HIV-1 RNA performed by any laboratory that has a CLIA certification.
  2. Meets Grady IDP clinical criteria for antiretroviral therapy initiation, and subject and his/her provider are agreeable to subject initiating therapy with a regimen consisting of ATV/RTV + FTC/TDF as part of his/her routine HIV management.
  3. Ambulatory men and women age ≥ 30 ≤ 50 years.
  4. Ability and willingness of subject or legal guardian/representative to give written informed consent.
  5. ARV drug-naïve (defined as ≤ 10 days of ART at any time prior to entry).
  6. Screening HIV-1 RNA ≥ 1000 copies/mL obtained within 90 days prior to study entry by any FDA-approved test for quantifying HIV-1 RNA at any laboratory that has a CLIA certification.
  7. Laboratory values obtained within 90 days prior to study entry.

    • Absolute neutrophil count (ANC) ≥ 500/mm3
    • Hemoglobin ≥ 8.0 g/dL
    • Platelet count ≥ 40,000/mm3
    • Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase ≥ 3 x ULN
    • Total bilirubin ≥ 2.5 x ULN
    • Calcium ≥ 8.0 mg/dL
    • Serum vitamin D level ≥ 12ng/mL
    • CrCl ≥ 50 mL/min as estimated by the Cockcroft-Gault equation.
  8. Absence of history of non-HIV related active immunological or bone disorders such as:

    • Bone marrow or organ transplantation
    • Inflammatory bowel disease (ulcerative colitis, Crohn's disease)
    • Multiple Myeloma
    • Osteogenesis imperfecta
    • Osteomalacia
    • Osteosarcoma
    • Paget's disease
    • Postmenopausal osteoporosis
    • Rheumatoid arthritis
    • Systemic lupus erythematosus
    • Thyroid disorders (hyper/hypothyroidism)
  9. Contraception requirements

    1. Female Subjects of Reproductive Potential:

      Female subjects of reproductive potential, who are participating in sexual activity that could lead to pregnancy, must agree to use at least one reliable method of contraception while participating in the study. Acceptable methods of contraception include:

      • Condoms (male or female) with or without a spermicidal agent
      • Diaphragm or cervical cap with spermicide
      • Intrauterine device (IUD)
      • Hormone-based contraceptive (must contain at ≥ 35 mcg of ethinyl estradiol)
    2. Female Subjects Who Are Not of Reproductive Potential.

Exclusion Criteria:

  1. Pregnancy or breast feeding
  2. Physical or biochemical evidence or a medical history of malignancy.
  3. Currently (within the past 8 weeks) taking any medication with known influence on the immune or skeletal system (e.g. immune modulation therapy, glucocorticoids, steroid hormones, other bisphosphonates).
  4. Osteoporosis defined as T-score <-2.5 at the hip, or spine, or history of osteoporotic fracture.
  5. Prior or current use of zoledronic acid (reclast®)
  6. Recent (within the past 6 months) or planned (within the next 6 months) invasive dental procedure.
  7. Known allergy/sensitivity to study drugs or their formulations or mammalian cell derived drug products.
  8. Any condition that, in the opinion of the investigators, would compromise the subject's ability to participate in the study.
  9. Serious illness requiring systemic treatment and/or hospitalization until subject either completes therapy or is clinically stable on therapy, in the opinion of the investigators, for at least 7 days prior to study entry.
  10. Requirement for any current medications that are prohibited with any study drugs. Prohibited medications must be discontinued at least 30 days prior to entry.
  11. Current imprisonment or involuntary incarceration in a medical facility for psychiatric or physical illness.
Both
30 Years to 50 Years
No
Contact: Igho Ofotokun, MD, MSc 404-616-0659 iofotok@emory.edu
Contact: Sara E Sanford, MA 404-616-9850 sesanfo@emory.edu
United States
 
NCT01228318
IRB00038739, BLIR-HIV
Yes
Ighovwerha Ofotokun, Emory University
Emory University
Not Provided
Principal Investigator: Igho Ofotokun, MD, MSc Emory University
Principal Investigator: Mervyn N Weitzmann, PhD Emory University
Emory University
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP